Display Settings:


Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Cancer Cell. 2012 Jul 10;22(1):7-8. doi: 10.1016/j.ccr.2012.06.009.

The future of cancer treatment: will it include immunotherapy?

Author information

  • 1Diabetes Center, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA. jeff.bluestone@ucsf.edu


Negative immune regulatory pathways inhibit anti-cancer T cell responses, preventing effective immune surveillance. Two clinical trials using monoclonal antibodies that antagonize the PD-1/PD-L1 pathway recently reported regression in several tumor types. In one of these trials, efficacy was linked to the expression of the PD-L1 biomarker on tumor cells.

Copyright © 2012 Elsevier Inc. All rights reserved.

Comment on


Publication Types

Publication Types

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk